PI3K

[Rhizen Pharmaceuticals (BusinessNewsWire, Inc.)] Rhizen Pharmaceuticals AG announced that it has commenced dosing in a Phase II trial to evaluate Tenalisib in patients with locally advanced or metastatic breast cancer.

[Aging] Cell functional experiments revealed that lncRNA DARS-AS1 participated in enhancing lung adenocarcinoma proliferation, invasion, and migration by inhibiting miR-188-5p.

[Journal of Molecular Histology] The authors investigated whether stromal cell-derived factor (SDF)-1 secreted by mesenchymal stem cells contributed to endothelial progenitor cell migration to ischemic sites via CXCR4/Phosphoinositide 3-Kinases/protein kinase B signaling pathway.

[npj Precision Oncology] A patient-derived cell line obtained at the time of disease progression was used to identify NRAS gene amplification as an additional driver of drug resistance to combination EGFR/MET therapies.

[Cell Death & Disease] Through an LC–MS assay, LIM and SH3 protein 1 (LASP1) was identified as a sphingolipid-metabolism-involved protein, and short-chain enoyl-CoA hydratase (ECHS1) was identified as a new LASP1-interacting protein through a protein assay in colorectal cancer.

[European Journal of Cancer] Murine breast cancer cells were grown in both immune-competent and -deficient BALB/c mice, and tumors were irradiated by three fractions of 24 Gy. A PD-1 blockade and a phosphoinositide 3-kinase (PI3K)γδ inhibitor were then administered every other day for two weeks.